30
Participants
Start Date
March 31, 2013
Primary Completion Date
January 31, 2014
Study Completion Date
January 31, 2014
Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Participants received Recombinant Factor VIII (Rec. factor VIII) on-demand treatment for 12 weeks followed by a 12 weeks prophylaxis treatment phase. The dose and mode of prophylaxis treatment was 25 IU/Kg, 3 times/per week. The dose in on-demand treatment was decided by physician according to the package insert or the current standard of care.
Beijing
Wuhan
Guangzhou
Beijing
Tianjin
Lead Sponsor
Bayer
INDUSTRY